Novo Nordisk (Germany) Probability of Future Stock Price Finishing Under 126.22
| NOVA Stock | EUR 100.50 0.50 0.50% |
Novo |
Novo Nordisk Target Price Odds to finish below 126.22
The tendency of Novo Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under € 126.22 after 90 days |
| 100.50 | 90 days | 126.22 | about 98.0 |
Based on a normal probability distribution, the odds of Novo Nordisk to stay under € 126.22 after 90 days from now is about 98.0 (This Novo Nordisk AS probability density function shows the probability of Novo Stock to fall within a particular range of prices over 90 days) . Probability of Novo Nordisk AS price to stay between its current price of € 100.50 and € 126.22 at the end of the 90-day period is about 80.81 .
Assuming the 90 days trading horizon Novo Nordisk has a beta of 0.0331. This indicates as returns on the market go up, Novo Nordisk average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Novo Nordisk AS will be expected to be much smaller as well. Additionally Novo Nordisk AS has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Novo Nordisk Price Density |
| Price |
Predictive Modules for Novo Nordisk
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Novo Nordisk AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Novo Nordisk Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Novo Nordisk is not an exception. The market had few large corrections towards the Novo Nordisk's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Novo Nordisk AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Novo Nordisk within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.31 | |
β | Beta against Dow Jones | 0.03 | |
σ | Overall volatility | 8.43 | |
Ir | Information ratio | -0.24 |
Novo Nordisk Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Novo Nordisk for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Novo Nordisk AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Novo Nordisk AS generated a negative expected return over the last 90 days | |
| Novo Nordisk AS has accumulated 20.77 B in total debt with debt to equity ratio (D/E) of 9.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novo Nordisk AS has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity. |
Novo Nordisk Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Novo Stock often depends not only on the future outlook of the current and potential Novo Nordisk's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Novo Nordisk's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.2 B |
Novo Nordisk Technical Analysis
Novo Nordisk's future price can be derived by breaking down and analyzing its technical indicators over time. Novo Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Novo Nordisk AS. In general, you should focus on analyzing Novo Stock price patterns and their correlations with different microeconomic environments and drivers.
Novo Nordisk Predictive Forecast Models
Novo Nordisk's time-series forecasting models is one of many Novo Nordisk's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Novo Nordisk's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Novo Nordisk AS
Checking the ongoing alerts about Novo Nordisk for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Novo Nordisk AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Novo Nordisk AS generated a negative expected return over the last 90 days | |
| Novo Nordisk AS has accumulated 20.77 B in total debt with debt to equity ratio (D/E) of 9.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novo Nordisk AS has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity. |
Additional Information and Resources on Investing in Novo Stock
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out Novo Nordisk Backtesting, Novo Nordisk Valuation, Novo Nordisk Correlation, Novo Nordisk Hype Analysis, Novo Nordisk Volatility, Novo Nordisk History as well as Novo Nordisk Performance. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.